# Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

> **NCT04057261** · PHASE3 · WITHDRAWN · sponsor: **RWTH Aachen University**

## Conditions studied

- Type 2 Diabetes
- Cardiovascular Diseases

## Interventions

- **DRUG:** Liraglutide Pen Injector [Victoza]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04057261
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11
- **Primary completion:** 2022-08
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** A study start is currently not foreseeable for organizational reasons. Due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial.
- **Last updated:** 2021-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04057261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04057261, "Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04057261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*